Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Sartorius Stedim Biotech acquires majority stake in U.S. start-up AllPure Technologies


Print article Print article
© Business Wire 2014
2014-04-28 08:22:03 -

Regulatory News.

Sartorius Stedim Biotech (SSB)(Paris:DIM), a leading international supplier for the pharmaceutical and biotech industries, announced that it has signed a contract to acquire the majority stake in the U.S.

start-up AllPure Technologies LLC. The privately owned company based in New Oxford, Pennsylvania, USA, has been operating on the market for four years, and in 2013 earned revenue of around U.S. $3 million with 25 employees. AllPure specializes in innovative single-use components for biopharmaceutical applications, such as aseptic sampling techniques. The parties agreed not to disclose any further details of the purchase agreement.

Reinhard Vogt, member of SSB’s Executive Board commented: “AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently.

I am really looking forward to working with the AllPure team and to all that we can accomplish together.”


“We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products,” said Michael Zumbrum, President of AllPure.



Profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx.

3,300 people, and in 2013 earned sales revenue of 588.4 million euros.

" title="http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140427005062r1&sid=16929&distro=ftp\"/>" target="_blank" rel="nofollow">cts.businesswire.com/ct/CT?id=bwnews&sty=20140427005062r1&am ..

Sartorius Stedim BiotechPetra Kirchhoff, +49(0)551-308-1686Vice
President of Corporate Communications petra.kirchhoff@sartorius.com : mailto:petra.kirchhoff@sartorius.com


Author:
Hossam Abdel-Kader
e-mail
Web: www.pr-inside.com/
Phone: +43 1 9582319

Disclaimer: (c) 2014 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com